Roquette H1 Turnover Reaches €2.59 Billion as Protein Volumes Grow
Updated: Oct 7
Roquette reported first half 2026 turnover of €2.586 billion, up 9 percent from a year earlier, as the plant based ingredients and pharmaceutical group continued integrating a broader portfolio. Current EBITDA rose 18 percent to €337 million and the current EBITDA margin increased to 13.0 percent.
The headline growth was not entirely organic. On a like for like basis, Roquette reported a 2 percent decline in both turnover and current EBITDA, showing that portfolio changes and mix helped offset a difficult underlying market environment.
Within Nutrition and Bioindustry, Roquette said its proteins business increased both volumes and sales compared with the first half of 2025. The company highlighted momentum in Europe and North America as it expands its position in higher value pea ingredients, while proteins and fibers continued to develop in line with its strategic plan.
Performance was also strong in parts of Asia, particularly India, according to the company. Roquette separately reported sustained commercial momentum in China, making the two markets important contributors to its geographic growth story.
The picture was more mixed in Health and Pharma. Cellulose and alginates supported results, while starch and capsule businesses continued to face competition and price pressure. That split illustrates the uneven demand environment across ingredient and specialty material markets.
Free cash flow improved to negative €54 million from negative €150 million in the first half of 2025, excluding the cash impact of the IFF Pharma Solutions acquisition. Roquette also issued €600 million of perpetual hybrid bonds in April to strengthen its financial position.
Roquette said its Shift and Lead transformation program has already generated more than €60 million of benefits. For food ingredient buyers and competitors, the half year results show a company leaning further into higher value proteins, fibers and specialty ingredients even as traditional starch markets remain challenging.
Comments